Avenue Therapeutics (ATXI) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
The meeting was called to order by the CEO, who welcomed attendees and introduced the board of directors and key participants, including legal counsel and independent auditors.
The agenda included accepting motions, collecting votes, and reporting results, with instructions for submitting questions online.
Board and executive committee updates
Directors present included Jay Kranzler, Faith Charles, Neil Herskowitz, Curtis Oltmans, Lindsay A. Rosenwald, and Alexandra MacLean.
Shareholder proposals
Three motions were presented: election of directors, ratification of KPMG LLP as auditors for 2024, and amendment of the 2015 Incentive Plan to increase authorized shares and extend its term.
The amendment also increased the annual share limit for non-employee director awards to 500,000.
Latest events from Avenue Therapeutics
- Q2 2026 saw a $0.7M net loss, no revenue, and cash reserves drop to $1.9M.ATXI
Q2 2026 - Q1 2026 net loss narrowed, but ongoing funding needs and going concern risks persist.ATXI
Q1 2026 - 2025 net loss narrowed to $2.9M as focus shifts to ATX-04 and IV tramadol amid funding challenges.ATXI
Q4 2025 - All directors were elected and KPMG LLP was ratified as auditor for 2025.ATXI
AGM 2025 - Seeks up to $35M to fund neurologic drug pipeline amid high risk and Fortress Biotech control.ATXI
Registration Filing - Stockholders will elect directors, ratify KPMG as auditor, and review governance and compensation.ATXI
Proxy Filing - Net loss narrowed to $2.2M as R&D costs fell and $1.4M revenue was recognized from AnnJi deal.ATXI
Q3 2025 - Returned to profitability in Q2 2025 on AnnJi deal revenue, but funding risks remain.ATXI
Q2 2025 - AJ201 trial nears topline data as net loss narrows and funding needs persist.ATXI
Q3 2024